START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
This article was originally published in Start Up
In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
You may also be interested in...
START-UP’s 2013 Life Science Venture Capital Survey: Lights, Even Exits, At The End Of A Dark Tunnel
Our third annual survey of institutional and corporate VCs arrives as life science investing reaches a crossroads. Public markets are gung ho for new biotech companies, lifting the spirits of a subset of our respondents, but VCs still face big hurdles to raise new funds.
Looking ahead to Start-Up’s third annual life science venture survey, optimism seems on the upswing and FOTF looks for an even stronger pace of IPOs in the second half of 2013. Plus news on financings by Agios, Merrimack, OncoMed and Alcresta.
A poll of 100 life science VCs reveals fears of industry contraction, increased importance of corporate investors, and attitudes on regulators, therapeutic areas and new investment models.